Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy

Blood Reviews

Volumn 13, Issue 3, 1999, Pages 127-146

  Clark, P ^a   Greer, I A ^a   Walker, I D ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; BLOOD CLOTTING FACTOR 5 DEFICIENCY; FETUS WASTAGE; HEMOSTASIS; HYPERHOMOCYSTEINEMIA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

EID: 0032825760     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.1999.0114     Document Type: Review

References (281)

1. Boisclair M. D., Ireland H., Lane D. A. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Reviews. 4(1):1990;25-40.
2. Martinelli I., Bottasso B., Duca F., Faioni E., Mannucci P. M. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 75(5):1996;703-705.
3. Simioni P., Scarano L., Gavasso S. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol. 92(2):1996;435-441.
4. Zoller B., Holm J., Svensson P., Dahlback B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous ARG506 to Gln mutation in the factor V gene (APC-Resistance) and/or inherited protein S deficiency. Thromb Haemost. 75(2):1996;270-274.
5. Kyrle P. A., Stumpflen A., Hirschl M. Levels of prothrombin fragment F1+2 is patients with hyperhomocysteinemia and a history of venous thrombosis. Thromb Haemost. 78:1997;1327-1331.
6. Moore K. L., Esmon C. T., Esmon N. L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 73(1):1989;159-165.
7. Lentz S. R., Tsiang M., Sadler J. E. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood. 77(3):1991;542-550.
8. Kurosawa S., Stearns-Kurosawa D. J., Hidari N., Esmon C. T. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest. 100(2):1997;411-418.
9. De Moerloose P., Mermillod N., Amiral J., Reber G. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: Comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. Thromb Haemost. 79(3):1998;554-556.
10. Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 79(6):1998;1166-1170.
11. Airoldi L., Gaffuri B., Rossi G. Soluble intercellular adhesion molecule-1 serum profile in physiological and pre-eclamptic pregnancy. Am J Reprod Immunol. 39(3):1998;183-188.
12. Clark P., Boswell F., Greer I. A. Neutrophils and pre-eclampsia. Semin Reprod Endocrinol. 16(1):1998;57-65.
13. Dahlback B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 90(3):1993;1004-1008.
14. Poort S. R., Rosendaal F. R., Reitsma P. H., Bertina R. M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88(10):1996;3698-3703.
15. Kang S. S., Wong P. W. K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease. Am J Hum Genet. 48:1991;536-539.
16. Lentz S. R., Sadler J. E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906-1914.
17. Cariou R., Tobelem G., Bellucci S. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells-Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost. 60(1):1988;54-58.
18. Ehrenforth S., Radtke K. P., Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost. 74(2):1995;797-798.
19. Martorell J. R., Munoz-Castillo A., Gil J. L. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract. Thromb Haemost. 74(2):1995;796-797.
20. Rodgers G. M., Conn M. T. Homocysteine, an atherogenic stimulus reduces protein C activation by arterial and venous endothelial cells. Blood. 75(4):1990;895-901.
21. Wilson B. D., Pitas R. E., Rodgers G. M. Regulation of endothelial cell protein C activation by native and oxidized low density lipoprotein. Semin Thromb Hemost. 18(1):1992;1117-1119.
22. Oida K., Tohda G., Ishii H. Effect of oxidized low density lipoprotein on thrombomodulin expression by THP-1 cells. Thromb Haemost. 78:1997;1228-1233.
23. Rai R. S., Regan L., Chitolie A., Donald J. G., Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol. 103(8):1996;842-844.
24. Preston F. E., Rosendaal F. R., Walker I. D. Increased fetal loss in women with heritable thrombophilia. Lancet. 348:1996;913-916.
25. Metz J., Kloss M., Omalley C. J. Prevalence of factor V Leiden is not increased in women with recurrent miscarriage. Clin App Thromb Hemost. 3(2):1997;137-140.
26. Cohen H., Holmes Z., Atoyebi W., Pickering W., Regan L. Factor V Leiden mutation and acquired activated protein C resistance in women with recurrent miscarriage. Thromb Haemost. (Suppl 1):1997;2978.
27. Lindoff C., Ingemarsson I., Martinsson G., Segelmark M., Thysell H., Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol. 176(2):1997;457-460.
28. Balasch J., Reverter J. C., Fabregues F. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod. 12(5):1997;1094-1097.
29. Trauscht Van Horn J. J., Capeless E. L., Easterling T. R., Bovill E. G. Pregnancy loss and thrombosis with protein C deficiency. Am J Obstet Gynecol. 167 (4 Pt 1):1992;968-972.
30. Sanson B. J., Friederich P. W., Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 75(3):1996;387-388.
31. De Vries J. I. P., Dekker G. A., Huijgens P. C., Jakobs C., Blomberg B. M. E., van Geijn H. P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 104:1997;1248-1254.
32. Dekker G. A., Devries J. I. P., Doelitzsch P. M. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol. 173(4):1995;1042-1048.
33. van Hinsberg V., Bertina R., van Wijngaarden A., van Tilberg N., Emeis J. J., Haverkate F. Activated protein C decreases plasminogen activator inhibitor activity in endothelial cell-conditioned medium. Blood. 65:1985;441-451.
34. Fukudome K., Kurosawa S., Stearns-Kurosawa D. J., He X., Rezaie A. R., Esmon C. T. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem. 271(29):1996;17491-17498.
35. Regan L. M., Stearns-Kurosawa D. J., Kurosawa S., Mollica J., Fukudome K., Esmon C. T. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem. 271(29):1996;17499-17503.
36. Laszik Z., Mitro A., Taylor F. B., Ferrell G., Esmon C. T. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 96(10):1997;3633-3640.
37. Marcum J. A., Rosenberg R. D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochem J. 23:1984;1730-1732.
38. Jesty J., Lorenz A., Rodriguez J., Wun T. C. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood. 87:1996;2301-2307.
39. ten Cate J. W., van der Poll T., Levi M., ten Cate H., van Deventer S. J. H. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost. 78(1):1997;415-419.
40. Edgington T. S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 66:1991;67-79.
41. Boehme M. W., Schmitt W. H., Youinou P., Stremmel W. R., Gross W. L. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med. 101(4):1996;387-394.
42. Conway E. M., Rosenberg R. D. Tumour necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 8:1988;5588-5592.
43. Moore K. L., Andreoli S. P., Esmon N. L., Esmon C. T., Bang N. U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 79:1987;124-130.
44. Vu T. K. H., Hung D. T., Wheaton V. I., Coughlin S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1991;1057-1068.
45. Ogltetree M. L. Thrombin receptor-mediated signalling in endothelial cells. Vane J. R., Born G. V. R., Welzel D. The endothelial cell in health and disease. 1995;85-96 Schattauer, Stuttgart.
46. Bartha K., Brisson C., Archipoff G. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem. 268:1993;421-429.
47. Maruyama Y., Maruyama I., Soejima Y. Thrombin receptor agonist peptide decreases thrombomodulin activity in cultured umbilical vein endothelial cells. Biochem Biophys Res Commun. 199:1994;1262-1269.
48. Clark P., Boswell F., Pearson C. W, Greer IA. Thrombin induction of ICAM-1 on monocytes and the relationship between monocyte ICAM-1 and plasma ICAM-1 in pregnancy. Haematologica. 84(EHA-4 Abstract Book):1999;184.
49. Chamouard P., Grunebaum L., Wiesel M. L. Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 7(12):1995;1183-1188.
50. Smith C. J., Haire W. D., Kaufman S. S., Mack D. R. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease. Am J Gastroenterol. 91(6):1996;1221-1225.
51. Bauer K. A., Rosenberg R. D. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 70(2):1987;343-350.
52. de Boer K., ten Cate J. W., Sturk A., Borm J. J., Treffers P. E. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol. 160(1):1989;95-100.
53. Miletich J. P., Sherman I., Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. New Engl J Med. 317:1987;991-996.
54. Tait R. C., Walker I. D., Reitsma P. H. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 73(1):1995;87-93.
55. Tait R. C., Walker I. D., Islam S. I. Protein C activity in healthy volunteers - influence of age, sex, smoking and oral contraceptives. Thromb Haemost. 70:1993;281-285.
56. Conlan M. G., Folsom A. R., Finch A., Davis C. E., Sorlie P., Wu K. K. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 70(5):1993;762-767.
57. Woodward M., Lowe G. D. O., Rumley A. Epedemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 97:1997;785-797.
58. Kessler C. M., Szymanski L. M., Shamsipour Z., Muesing R. A., Miller V. T., LaRosa J. C. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol. 89(3):1997;326-331.
59. Habiba M., Andrea A., Phipps B., al-Azzawi F. Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch. Eur J Obstet Gynecol Reprod Biol. 66(2):1996;165-168.
60. Cooper D. N., Tuddenham E. G. D., Meade T. W. The molecular genetics of familial venous thrombosis. Clinical Haematology: Thrombophilia. 1994;Balliere Tindall, London. p. 637-674.
61. Faioni E. M., Franchi F., Asti D., Sacchi E., Bernardi F., Mannucci P. M. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost. 70(6):1993;1067-1071.
62. Cooper P. C., Hampton K. K., Makris M., Abuzenadah A., Paul B., Preston F. E. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol. 88(1):1994;201-203.
63. Vigano Dangelo S., Mazzola G., Della Valle P., Testa S., Pattarini E., Dangelo A. Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays. Thromb Res. 77(4):1995;375-378.
64. Griffen J. H., Evatt B., Wideman C., Fernandez J. A. Anticoagulant protein C pathway defective in the majority of thrombophilic patients. Blood. 82:1993;1989-1993.
65. Koster T., Rosendaal F. R., de Ronde H., Briet E., Vandenbroucke J. P., Bertina R. M. Leiden thrombophilia study. Lancet. 342:1993;1503-1506.
66. Bertina R. M., Koeleman B. P. C., Koster T. Mutation in blood-coagulation factor-V associated with resistance to activated protein-C. Nature. 369(6475):1994;64-67.
67. Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
68. Cumming A. M., Tait R. C., Fildes S., Yoong A., Keeney S., Hay C. R. Development of resistance to activated protein C during pregnancy. Br J Haematol. 90(3):1995;725-727.
69. Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. Haemostatic variables in normal pregnancy. Thromb Haemost. (Suppl 1):1997;731.
70. Olivieri O., Frisco S., Manzato F. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 91:1995;465-470.
71. Williamson D., Brown K., Luddington R., Baglin C., Baglin T. Factor V Cambridge: a new mutation (Arg306-〉Thr) associated with resistance to activated protein C. Blood. 91(4):1998;1140-1144.
72. Clark P., Walker I. D., Greer I. Acquired activated protein C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet. 353:1999;292-293.
73. de Visser M. C. H., Rosendaal F. R., Bertina R. M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 93(4):1999;1271-1276.
74. Jorquera J. I., Montoro J. M., Fernandez M. A. Modified test for activated protein C resistance. Lancet. 344:1994;1162-1163.
75. Trossaert M., Conard J., Horellou M. H. Modified APC resistance assay for patients on oral anticoagulants. Lancet. 344:1994;1709.
76. Wen D. Z., Dittman W. A., Ye R. D., Deaven L. L., Majerus P. W., Sadler J. E. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochem J. 26(14):1987;4350-4357.
77. Espinosa R., Sadler J. E., Le Beau M. M. Regional localisation of the human thrombomodulin gene to 20p12-cen. Genomics. 5:1989;649-650.
78. Healy A. M., Rayburn H. B., Rosenberg R. D., Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before the development of a functional cardiovascular system. Proc Natl Acad Sci USA. 92:1995;850-854.
79. Weiler-Guettler H., Christie P. D., Beeler D. L. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 101(9):1983;1983-1991.
80. Norlund L., Holm J., Zoller B., Ohlin A. K. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost. 77(2):1997;248-251.
81. van der Velden P. A., Krommenhoek-Van Es T., Allart C. F., Bertina R. M., Reitsma P. H. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost. 65(5):1991;511-513.
82. Doggen C. J., Kunz G., Rosendaal F. R. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost. 80(5):1998;743-748.
83. Esmon C. T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 264:1989;4743-4746.
84. Takano S., Kimura S., Ohdama S., Aoki N. Plasma thrombomodulin in health and diseases. Blood. 76:1990;2024-2029.
85. Endo S., Inada K., Nakae H. Blood levels of endothelin-1 and thrombomodulin in patients with disseminated intravascular coagulation and sepsis. Res Commun Mol Pathol Pharmacol. 90(2):1995;277-288.
86. Bontis J., Vavilis D., Agorastos T., Zournatzi V., Konstantinidis T., Tagou K. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol Reprod Biol. 60(2):1995;139-141.
87. Boehme M. W., Nawroth P. P., Kling E. Arth Rheum. 37(4):1994;572-527.
88. Boehme M. W., Werle E., Kommerell B., Raeth U. Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria. Clinical Investigator. 72(8):1994;598-603.
89. Brenton D. P., Cusworth D. C., Gaull G. E. Homocystinuria: metabolic studies on three patients. J Pediat. 67:1965;58-68.
90. Ueland P. M., Refsum H., Brattstrom L., Franceis R. B. J. Plasma homocysteine and cardiovascular disease. Atherosclerotic cardiovascular disease, haemostasis and endothelial function. 1992;Dekker, New York. p. 183.
91. Harker L. A., Harlan J. M., Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circul Res. 53(6):1983;731-739.
92. Wilken D. E. L., Wilken B. The pathogenesis of coronary artery disease - A possible role for methionine metabolism. J Clin Invest. 58:1976;1079-1082.
93. Brattstrom L., Tengborn L., Lagerstedt C., Israelson B., Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis. 21:1991;51.
94. Bienvenu T., Ankri A., Chadefaux B., Montalescot G., Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res. 70(2):1993;123-129.
95. Amundsen T., Ueland P. M., Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol. 15(9):1995;1321-1323.
96. Fermo I., Vigano D. A. S., Paroni R. Prevalence of moderate hyperhomocysteinaemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 123(10):1995;747-753.
97. Cattaneo M., Martinelli I., Mannucci P. M. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. New Engl J Med. 335(13):1996;974-975.
98. Kang S. S., Zhou J., Wong P. W. K., Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylene tetrahydrofolate reductase. Am J Hum Genet. 43:1988;414-417.
99. Motulsky A. G. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Gen. 58(1):1996;17-20.
100. Wall R. T., Harlan J. M., Harker L. A., Striker G. E. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res. 18(1):1980;113-121.
101. Rodgers G. M., Kane W. H. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 77(6):1986;1909-1916.
102. Pasatharathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 917:1987;337.
103. Lentz S. R., Sadler J. E. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood. 81(3):1993;683-689.
104. Upchurch G. R. Jr, Welch G. N., Fabian A. J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272(27):1997;17012-17017.
105. Upchurch G. R., Welch G. N., Freedman J. E., Loscalzo J. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated injury. Circulation. 92:1995;228-230.
106. de Jong S. C., Stenhouver C. D. A., van den Berg M., Vischer U. M., Rauwerda J. A., Emeis J. J. Endothelial marker proteins in hyperhomocysteinaemia. Thromb Haemost. 78:1997;1332-1337.
107. Mercie P., Seigneur M., Parrot F., Fialon P., Boisseau M. R., Conri C. Endothelial injury markers in hyperhomocysteinemic patients. Thromb Haemost. (Suppl):1997;532.
108. Alessandri C., Basili S., Maurelli M. Relationship between prothrombin activation fragment F1+2 and serum cholesterol. Haemostasis. 26(4):1996;214-219.
109. Broijersen A., Hamsten A., Silveira A. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost. 76(2):1996;171-176.
110. Gianturco S. H., Eskin S. G., Navarro L. T. Abnormal effects of hypertriglycerloemic very low density lipoproteins on 3-hydroxy-methylglutaryl-CoA reductase activity and viability of bovine cultured endothelial cells. Biochim Biophys Acta. 618:1980;143-152.
111. Spiedel M. T., Booyse F. M., Abrams A., Moore M. A., Chung B. H. Lipolysed hypertrigyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoprotein inhibits this cytotoxicity. Thromb Res. 58:1990;251-264.
112. Stewart D. J., Monge J. C. Hyperlipidaemia and endothelial dysfunction. Curr Opin Lipidol. 4:1993;319-324.
113. Kawasaki T., Kambayashi J. I., Ariyoshi H., Sakon M., Suehisa E., Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res. 88(1):1997;67-73.
114. Mitropoulos K. A. Lipid-thrombosis interface. Br Med Bull. 50(4):1994;813-832.
115. Conlan M. G., Folsom A. R., Finch A. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. The atherosclerosis Risk in Communities (ARIC) Study Investigators. Thromb Haemost. 72(4):1994;551-556.
116. Sattar N., Greer I. A., Louden J. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small dense low density lipoprotein. J Clin Endo Metab. 82:1997;2483-2491.
117. Ishii H., Kizaki K., Horie S., Kazama M. Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes. J Biol Chem. 271(14):1996;8458-8465.
118. Berg K. A new serum type system in man. Acta Pathol Microbiol Scand. 59:1963;369-392.
119. Dahlen G. H., Guyton J. R., Attar M., Farmer J. A., Kautz J. A., Gotto A. M. Association of levels of lipoprotein(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765.
120. Scott J. Lipoprotein(a). BMJ. 303:1991;663-664.
121. Yamazaki M., Asakura H., Jokaji H. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost. 71(4):1994;424-427.
122. Bandello F., Vigano D. A. S., Parlavecchia M. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost. 72(1):1994;39-43.
123. Utermann G., Menzel H. J., Kraft H. G., Duba H. C., Kemmler H. G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 80:1987;458-465.
124. Lindahl G., Gersdorf W., Menzel H. J. The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Hum Genet. 81:1989;149-152.
125. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risk associated with lipoprotein (a). Nature. 339:1989;301-303.
126. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 266(4):1991;2459-2465.
127. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherslcerosis. Nature. 339:1989;303-305.
128. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyses binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA. 86:1989;3847-3851.
129. Sporn M. B., Roberts A. B., Wakefield L. M., Assoian R. L. Transforming growth factor-B: Biological function and chemical structure. Science. 233:1986;532-534.
130. Graham C. H., Lysiak J. J., McCrae K. R., Lala P. K. Localization of transforming growth factor-beta at the human fetal-maternal interface: role in trophoblast growth and differentiation. Biol Reprod. 46(4):1992;561-572.
131. Graham C. H. Effect of transforming growth factor-beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts. Placenta. 18(2-3):1997;137-143.
132. Stirling Y., Woolf L., North W. R. S., Seghatchian M. J., Meade T. W. Haemostasis in normal pregnancy. Thromb Haemost. 52(2):1984;176-182.
133. Mitropoulos K. A., Martin J. C., Burgess A. I. The increased rate of activation of factor XII in late pregnancy can contribute to the increased reactivity of factor VII. Thromb Haemost. 63(3):1990;349-335.
134. Scarabin P. Y., Bonithon-Kopp C., Bara L., Samama M., Blot P. Is factor VII activation in pregnant women relevant to fetal growth retardation. Thromb Res. 45:1987;845-850.
135. Lefkowitz J. B., Clarke A. H., Barbour L. A. Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol. 175(3):1996;657-660.
136. Mannucci P. M., Vigano S., Botasso B. Protein C antigen during pregnancy, delivery and the puerperium. Thromb Haemost. 52:1984;217.
137. Gonzalez R., Alberca I., Vicente V. Protein C levels in late pregnancy and in women on oral contraceptives. Thromb Res. 39:1985;637-640.
138. Gatti L., Tenconi P. M., Guarneri D. Hemostatic parameters and platelet activation by flow cytometry in normal pregnancy: a longitudinal study. Int J Clin Lab Res. 24:1994;217-219.
139. Malm J., Laurell M., Dalhback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 68:1988;437-443.
140. Cumming A. M., Tait R. C., Fildes S., Hay C. R. Diagnosis of APC resistance during pregnancy. Br J Haematol. 92(4):1996;1026-1029.
141. Clark P., Brennand J., Conkie J. A., McCall F., Greer I. A., Walker I. D. The effect of gestation on a chromogenic APC response assay. Thromb Haemost. (Suppl):1997;317.
142. Weiner C. P., Brandt J. Plasma antithrombin III activity in normal pregnancy. Obstet Gynecol. 56(5):1980;601-603.
143. Hellgren M., Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynaecol Obstet Invest. 12(3):1981;141-154.
144. Weenink G. H., Treffers P. E., Kahle L. H., ten Cate J. W. Antithrombin III in normal pregnancy. Thromb Res. 26:1982;281-287.
145. Bremme K., Ostlund E., Almqvist I., Heinonen K., Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol. 80(1):1992;132-137.
146. de Boer K., ten Cate J. W., Sturk A., Borm J. J. J., Treffers P. E. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol. 160(1):1989;95-100.
147. Reinthaller A., Mursch-Edlmayar G., Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy, with hypertensive disorders and after delivery. Br J Obstet Gynaecol. 97:1990;506-510.
148. Cadroy Y., Grandjean H., Pichon J. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol. 100(5):1993;416-420.
149. Comeglio P., Fedi S., Liotta A. A. Blood clotting activation during normal pregnancy. Thromb Res. 84(3):1996;199-202.
150. Delorme M. A., Burrows R. F., Orfosu F. A., Andrew M. Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost. 18(1):1992;81-90.
151. Nelson D. M., Crouch E. C., Curran E. M., Farmer D. R. Trophoblast interaction with fibrin matrix. Am J Pathol. 136:1990;855-865.
152. Bonnar J., Sheppard B. L. The vascular supply of the placenta in normal and abnormal pregnancy. Baustein A. Pathology of the female genital tract. 1977;673-689 Springer Verlag, New York.
153. Andrew M., Schmidt B., Mitchell L., Paes B., Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost. 63:1990;27-30.
154. Suzuki K., Nishioka J., Hashimoto S. Protein C inhibitor. Purification from human plasma and characterisation. J Biol Chem. 258:1983;163-168.
155. Heeb M. J., Espana F., Griffin J. H. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood. 73:1989;446-454.
156. van der Meer F. J. M., van Tilberg N. H., van Wijngaarden A., van der Linden I. K., Briet E., Bertina R. M. A second plasma inhibitor of activated protein C: alpha 1-antitrypsin. Thromb Haemost. 62(2):1989;756-762.
157. Marlar R. A., Kressin D. C., Madden R. M. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma. Thromb Haemost. 69(1):1993;16-20.
158. Hoogendoorn H., Toh C. H., Nesheim M. E., Giles A. R. Alpha 2-macroglobulin binds and inhibits activated protein C. Blood. 78(9):1991;2283-2290.
159. Gruber A., Griffen J. H. Direct detection of activated protein C in blood from human subjects. Blood. 79:1992;2340-2348.
160. Bauer K. A., Kass B. L., Beeler D. L., Rosenberg R. D. Detection of protein C activation in humans. J Clin Invest. 74:1984;2033-2041.
161. Bauer K. A., Weiss L. M., Sparrow D., Vokomas P. S., Rosenberg R. D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. J Clin Invest. 80:1987;1527.
162. Espana F., Gilabert J., Vicente V. Activated protein C: alpha 1-antitrypsin (APC:alpha 1 AT) complex as a marker for in vitro diagnosis of prethrombotic states. Thromb Res. 66(5):1992;499-508.
163. Espana F., Gilabert J., Aznar J., Estelles A., Kobayashi T., Griffin J. H. Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. Am J Obstet Gynecol. 164(5 Pt 1):1991;1310-1316.
164. Wagner D. D. Cell biology of von-Willebrand factor. Ann Rev Cell Biol. 6:1990;217-246.
165. Pottinger B. E., Read R. C., Paleolog E. M., Pearson J. D. Von Willebrand factor is an acute phase reactant in man. Thromb Res. 53:1989;387-394.
166. Deng L., Bremme K., Hansson L. O., Blomback M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol. 84(6):1994;941-945.
167. Nawroth P., Stern D. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 163:1986;740-745.
168. Ogawa S., Gerlach H., Esposito C., Pasagian-Macauley A., Brett J., Stern D. Hypoxia modulates the barrier and coagulant functions of cultured bovine endothelium. J Clin Invest. 85:1990;1090-1098.
169. Glaser C. B., Morser J., Clark J. H. Oxidation of a specific methionine in thrombomodulin by activated neutrophil product blocks cofactor activity. J Clin Invest. 90:1992;2565-2573.
170. Magriples U., Chan D. W., Bruzek D., Copel J. A., Hsu C. D. Thrombomodulin: a new marker for placental abruption. Thromb Haemost. 81(1):1999;32-34.
171. Boffa M. C., Valsecchi L., Fausto A. Predictive value of plasma thrombomodulin in pre-eclampsia and gestational hypertension. Haemost Thromb. 79(6):1998;1092-1095.
172. Silliman K., Shore V., Forte T. M. Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. Metabol Clin Exp. 43(8):1994;1035-1041.
173. Martin-Hidalgo A., Hom C., Belfrage M., Schotz M. C., Herrera E. Lipoproteinlipase and hormone-sensitive lipase activity and mRNA. Am J Physiol. 266:1994;930-935.
174. Grimbert S., Fromenty B. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to the development of acute fatty liver of pregnancy. Hepatology. 17:1993;628-637.
175. O'Sullivan A. J., Hoffman D. M., Ho K. K. Y. Estrogen, lipid oxidation and body fat. N Engl J Med. 333:1995;669-670.
176. Panteghini M., Pagani F. Serum concentrations of lipoprotein(a) during normal pregnancy and postpartum. Clin Chem. 37(11):1991;2009-2010.
177. Shaper A. G., MacIntosh D. M., Evans C. M., Kyope J. Fibrinolysis and plasminogen levels in pregnancy and the puerperium. Lancet. 2:1965;706-708.
178. Nakashimi A., Kobayashi T., Terao T. Fibrinolysis during normal pregnancy and severe pre-eclampsia relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest. 42(2):1996;95-101.
179. Meekins J. W., Pijnenborg R., Hanssens M., van Assche A., McFadyen I. R. Immunohistochemical detection of lipoprotein (a) in the wall of placental bed spiral arteries in normal and severe-pre-eclamptic pregnancies. Placenta. 15:1994;511-524.
180. Berg K., Roald B., Sande H. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation. Clin Gen. 46:1994;52-56.
181. Steegers-Theunissen R. P., Wathen N. C., Eskes T. K., van Raaij-Selten B., Chard T. Maternal and fetal levels of methionine and homocysteine in early human pregnancy. Br J Obstet Gynecol. 104(1):1997;20-24.
182. Andersson A., Hultberg B., Brattstrom L., Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem. 30(6):1992;377-379.
183. Walker M. C., Smith G. N., Perkins S. L., Keely E. J., Garner P. R. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol. 180(3 Pt 1):1999;660-664.
184. Andersson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelts A., Hulteberg B. Plasma homocysteine before and after methionine loading with regard
185. Wouters M. G., Moorrees M. T. Plasma homocysteine and menopausal status. Eur J Clin Invest. 25(11):1995;801-805.
186. Khong T. Y., de Wolf F., Robertson W. B., Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestation-age infants. Br J Obstet Gynaecol. 93:1986;1049-1059.
187. Zeek P. M., Assali N. S. Vascular changes with eclamptogenic toxaemia of pregnancy. Am J Obstet Gynecol. 20:1950;1099-1109.
188. Labarrere C. A. Acute atherosis. A histopathological hallmark of immune aggression. Placenta. 9:1988;95-108.
189. Lyall F., Greer I. A., Boswell F., Macara L. M., Walker J. J., Kingdom J. C. The cell adhesion molecule, VCAM-1, is selectively elevated in serum in preeclampsia: does this indicate the mechanism of leucocyte activation? Br J Obstet Gynaecol. 101(6):1994;485-487.
190. Redman, C. W. G. Allington, M. J. Bolton, F. G. Stirrat, G. M. Plasma beta thromboglobulin in pre-eclampsia. Lancet 1977(ii): 248.
191. Douglas J. T., Shah M., Lowe G. D. O. Plasma fibrinopeptide A and beta thromboglobulin in pre-eclampsia and pregnancy hypertension. Thromb Haemost. 47:1982;54-55.
192. Greer I. A., Calder A. A., Walker J. J., Lunan C. B., Tulloch I. Increased platelet reactivity in pregnancy-induced hypertension and uncomplicated diabetic pregnancy: an indication for anteplatelet therapy? Br J Obstet Gynecol. 5:1988;1204-1208.
193. Greer, I. A. Leask, R. Hodson, B. A. Endothelin, elastase and endothelial dysfunction in pre-eclampsia. Lancet 1991(i): 558.
194. Downing, I. Shepherd, G. L. Lewis, P. J. Reduced prostacyclin production in pre-eclampsia. Lancet 1980(ii): 1374.
195. Walsh S. W. Pre-eclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol. 152:1985;335-340.
196. Harlan J. D. Neutrophil-mediated vascular injury. Acta Med Scand. 715:1987;123-129.
197. Greer I. A., Haddad N. G., Dawes J., Johnstone F. D., Calder A. A. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynecol. 96:1989;978-982.
198. Barden A., Graham D., Beilin L. J. Neutrophil CD11B expression and neutrophil activation in pre-eclampsia. Clin Sci. 92(1):1997;37-44.
199. Sacks, G. P. Studena, K. Sargent, I. L. Redman, C. W. G. Normal pregnancy and pre-eclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. International Society for the Study of Hypertension in Pregnancy 1997, Lady Margaret Hall, Oxford, UK.
200. Austgulen R., Lien E., Vince G., Redman C. W. G. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 71:1997;53-58.
201. Smith C. W., Marlin S. D., Rothlein R., Toman C., Anderson D. C. Cooperative interactions of LFA-1 and Mac-1 with intracellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in-vitro. J Clin Invest. 83:1989;2008-2017.
202. Hynes R. O., Bader B. L. Targeted mutations in integrins and their ligands: their implications for vascular biology. Thromb Haemost. 78(1):1997;83-87.
203. Dustin M. L., Rotlein R., Bhan A. K., Dinarello C. A., Springer T. A. Induction by IL-1 and interferon gamma: tissue distribution, biochemistry and function of a natural adherence molecule ICAM-1. J Immunol. 137:1986;245-254.
204. Mattila P., Majuri M-L., Mattila P. S., Ronkonen R. TNF alpha induced expression of endothelial adhesion molecules ICAM-1 and VCAM-1 is linked to protein kinase C activation. Scand J Immunol. 36:1992;159-165.
205. Kupferminc M. J., Peaceman A. M., Wigton T. R., Rhenberg K. A., Socol M. L. Tumor necrosis factor alpha is elevated in plasma and amniotic fluid of patients with severe pre-eclampsia. Am J Obstet Gynecol. 170:1994;1752-1759.
206. Vince G. S., Starkey P. M., Austgulen R., Kwiatkowski D., Redman C. W. G. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol. 102:1995;20-25.
207. Greer I. A., Lyall F., Perera T., Boswell F., Macara L. M. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 84(6):1994;937-940.
208. Kupferminc M. J., Peaceman A. M., Aderka D., Wallach D., Socol M. L. Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe pre-eclampsia. Obstet Gynecol. 88(3):1996;420-427.
209. Wang Y., Walsh S. W. TNF alpha concentrations and mRNA expression are increased in pre-eclamptic placentas. J Reprod Immunol. 32:1996;157-169.
210. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA. 82:1985;8667-8671.
211. Ware J. A., Heistad D. D. Platelet-endothelial interactions. N Engl J Med. 328:1993;628-635.
212. Clark B. A., Halverson L., Sachs B., Epstein F. Plasma endothelin levels in pre-eclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol. 166:1992;962-968.
213. Lopez-Farre A., Riesco A., Moliz M. Inhibition by L-arginine of endothelin-mediated increase in cytosolic calcium in human neutrophils. Biochem Biophys Res Commun. 178:1991;884-891.
214. Ishida K., Takeshige K., Minakami S. Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun. 173:1990;496-500.
215. Riesco A., Carmelo C., Blum G. Nitric oxide-generating system as an autocrine mechanism in human polymorhonuclear leukocytes. Biochem J. 292:1993;791-796.
216. Gomez-Garre D., Guerra M., Gonzalez E. Aggregation of human polymorphonuclear leukocytes by endothelin. Eur J Pharmacol. 224:1992;167-172.
217. Lopez-Farre A., Riesco A., Espinosa G. Effect of endothlin-1 on neutrophil adhesion to endothelial cells and the perfused heart. Circul. 88:1993;1166-1171.
218. Cunningham M. E., Huribal M., Bala R. J., McMillen M. A. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Critical Care Medicine. 25(6):1997;958-964.
219. Baggiolini M., Waltz A., Kunel S. L. Neutrophil activating protein 1/interleukin-8, a novel cytokine that activates neutrophils. J Clin Invest. 84:1989;1045-1049.
220. Hustin J., Foidart J. M., Lambotte R. Maternal vascular lesions in pre-eclampsia and intrauterine growth retardation: light microscopy and immunofluorescence. Obstet Gynecol Surv. 40:1985;145-149.
221. Saleh A. A., Bottoms S. F., Ali A. M., Mariona F. G., Mammen E. F. Pre-eclampsia, delivery and the hemostatic system. Am J Obstet Gynecol. 157:1987;331-336.
222. Kobayashi T., Terao T. Pre-eclampsia as chronic intravascular coagulation. Gynecol Obstet Invest. 24:1987;170-178.
223. Halligan A., Bonnar J., Sheppard B., Darling M., Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynecol. 101:1994;488-492.
224. Caron C., Goudemand J., Marey A., Beague D., Ducroux G., Drouvin F. Are haemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension? Thromb Haemost. 66(4):1991;410-414.
225. Ramalakshmi B. A., Raju L. A., Raman L. Antithrombin III levels in pregnancy induced hypertension. Natl Med J India. 8(2):1995;61-62.
226. Hsu C. D., Lucas R. B., Johnson T. R., Hong S. F., Chan D. W. Elevated urine thrombomodulin/creatinine ratio in severely preeclamptic pregnancies. Am J Obstet Gynecol. 171(3):1994;854-856.
227. Hsu C. D., Copel J. A., Hong S. F., Chan D. W. Thrombomodulin levels in preeclampsia, gestational hypertension, and chronic hypertension. Obstet Gynecol. 86(6):1995;897-899.
228. Hsu C. D., Copel J. A., Chan D. W. Antepartum and postpartum thrombomodulin levels in preeclamptic and normotensive pregnancies. J Soc Gynecol Invest. 4(3):1997;135-137.
229. Paternoster D., Stella A., Simioni P., Trovo S., Plebani P., Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet. 47(3):1994;215-221.
230. Reith A., Booth N. A., Moore N. R., Cruikshank D. J., Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynecol. 100:1993;370-374.
231. Lorentzen B., Endersen M. J., Clausen T., Henriksen T. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop pre-eclampsia. Hypertens Preg. 13:1994;103-109.
232. Endersen M. J., Lorentzen B., Henriksen T. Increased lipolytic activity and high ratio of free fatty acids to albumin in sera from women with pre-eclampsia leads to triglyceride accumulation in cultured endothelial cells. Am J Obstet Gynecol. 167:1992;440-447.
233. Lorentzen B., Endresen M. J., Hovig T., Haug E., Henriksen T. Sera from pre-eclamtic women increase the content of triglycerides and reduce the release of prostacyclin in cultured endothelial cells. Thromb Res. 63:1991;353-372.
234. Lehr H. A., Krombach F., Munzing S. In vitro effects of oxidized low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo situation. Am J Pathol. 146(1):1995;218-227.
235. Kume N., Cybulsky M. I., Gimbrone M. A. Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 90:1992;1138-1144.
236. Brenner B., Shapira A., Bahari C., Haimovich L., Seligsohn U. Hereditary protein C deficiency during pregnancy. Am J Obstet Gynecol. 157(5):1987;1160-1161.
237. Franco R. F., Elion J., Tavella M. H., Santos S. E. B., Zago M. A. The prevalence of factor V Arg306-Thr (Factor V Cambridge) and factor V Arg306-Gly mutations in different human populations. Thromb Haemost. 1999(81):1999;312-313.
238. Chan W. P., Lee C. K., Kwong Y. L., Lam C. K., Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 91:1998;1135-1139.
239. Rotmensch S., Liberati M., Mittelmann M., BenRafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol. 177(1):1997;170-173.
240. Brenner B., Lanir N., Thaler I. HELLP syndrome associated with factor V R 506Q mutation. Br J Haematol. 92(4):1996;999-1001.
241. Dizon-Townson D. S., Nelson L. M., Easton K., Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 175(4 Pt 1):1996;902-905.
242. Grandone E., Margaglione M., Colaizzo D. Factor V Leiden, C〉T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemost. 77:1997;1052-1054.
243. van Pampus M. G., Wolf H., Buller H. R., Huijgens P. C., Jakobs P., Dekker G. A. Underlying disorders associated with severe pre-eclampsia and HELLP syndrome. Am J Obstet Gynecol. (Suppl):1997;26.
244. Lindqvist P. G., Svensson P. J., Marsal K., Grennert L., Luterkort M., Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost. 81:1999;532-537.
245. Rajkovic A., Catalano P. M., Malinow M. R. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol. 90(2):1997;168-171.
246. Laivuori H., Kaaja R., Turpeinen U., Viinikka L., Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol. 93(4):1999;489-493.
247. Mills J. L., McPartlin J. M., Kirke P. N. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet. 345:1995;149-151.
248. Lucock M. D., Wild J., Lumb C. H. Risk of neural tube defect-affected pregnancy is associated with a block in maternal one-carbon metabolism at the level of N-5-methyltetrahydrofolate:homocysteine methyltransferase. Biochem Molec Med. 61(1):1997;28-40.
249. Mills J. L., Scott J. M., Kirke P. N. Homocysteine and neural tube defects. J Nutrition. 126(3):1996;756S-760S.
250. Steegers-Theunissen R. P., Boers G. H., Trijbels F. J. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metab: Clin Exp. 43(12):1994;1475-1480.
251. Steegers-Theunissen R. P., Boers G. H., Blom H. J. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol. 172(5):1995;1436-1441.
252. Ubbink J. B. Is an elevated circulating maternal homocysteine concentration a risk factor for neural tube defects? Nutrition Reviews. 53(6):1995;173-175.
253. Leeda M., Riyazi N., de Vries J. I., Jakobs C., van Geijn H. P., Dekker G. A. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol. 179(1):1998;135-139.
254. van den Elzen H. J., Wladimiroff J. W., Cohen-Overbeek T. E., de Bruijn A. J., Grobbee D. E. Serum lipids in early pregnancy and risk of pre-eclampsia. Br J Obstet Gynecol. 103(2):1996;117-122.
255. Barkai G., Ries L., Lusky A., Korach J., Mashiach S., Schiff E. Second-trimester serum fluorescence polarization in patients who subsequently develop pregnancy-induced hypertension. Am J Perinatol. 13(6):1996;323-328.
256. Wang J., Mimuro S., Lahoud R., Trudinger B., Wang X. L. Elevated levels of lipoprotein(a) in women with preeclampsia. Am J Obstet Gynecol. 178(1 Pt 1):1998;146-149.
257. Sattar, N. Clark, P. Greer, I. A. Shepherd, J. Packard, C. J. Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. Atheroscler 1999: in press.
258. Poland B. J., Miller J. R. Reproductive counselling in patients who have had a spontaneous abortion. Am J Obstet Gynecol. 127:1977;685-591.
259. Stray-Pederson B., Stray-Pederson S. Etiological factors and subsequent reproductive performances in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol. 148:1984;142-146.
260. Silver M. M., Laxer R. M., Laskin C. A., Smallhorn J. F., Gare D. J. Association of fetal heart block and massive placental infarction due to maternal autoantibodies. Ped Pathol. 12(1):1992;131-139.
261. Dizon-Townson D. S., Meline L., Nelson L. M., Varner M., Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol. 177(2):1997;402-405.
262. Mandel H., Brenner B., Berant M. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. New Engl J Med. 334(12):1996;763-768.
263. Giusti B., Gori A. M., Attanasio M. Lupus Anticoagulant and monocyte procoagulant activity in polyabortive women. Autoimmunity. 15(4):1993;299-304.
264. Lamvik J., Odegaard O. R., Abildgaard U. Protein C deficiency. A possible cause of fetal death and recurrent venous thrombosis. Tidsskrift for Den Norske Laegeforening. 107(8):1987;739-740.
265. Gris J. C., Ripart-Neveu S., Maugard C. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost. 77(6):1997;1096-1103.
266. Grisaru D., Fait G., Eldor A. Activated protein C resistance and pregnancy complications. Am J Obstet Gynecol. 174(2):1996;801-802.
267. Brenner B., Mandel H., Lanir N. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 97(3):1997;551-534.
268. Rai R., Regan L., Hadley E., Dave M., Cohen H. Second trimester pregnancy loss is associated with activated protein-C resistance. Thromb Haemost. 73(6):1995;1300.
269. Rai R., Regan L., Hadley E., Dave M., Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 92(2):1996;489-490.
270. Dizon-Townson D. S., Kinney S., Branch D. W., Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 34(3):1997;217-223.
271. Grandone E., Margaglione M., Colaizzo D. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 77(5):1997;822-824.
272. GoddijnWessel T. A. W., Wouters M., Van der Molen E. F. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol. 66(1):1996;23-29.
273. Wouters M., Boers G. H. J., Blom H. J. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertility Sterility. 60(5):1993;820-825.
274. Nelen W. L. D. M., Steegers E. A. P., Eskes T. K. A., Blom H. J. Genetic risk factor for unexplained early pregnancy loss. Lancet. 350:1997;861.
275. Grandone E., Margaglione M., Colaizzo D. Methylene tetrahydrofolate reductase (MTHFR) 677T-〉C mutation and unexplained early pregnancy loss. Thromb Haemost. 79(5):1998;1056-1057.
276. Gris J-C., Quere I., Monpeyroux F. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent. Thromb Haemost. 81:1999;891-899.
277. Vogel J. J., Bounameaux H. Protein C deficiency and pregnancy: a case report. Obstet Gynecol. 73(3 Pt 2):1989;455-456.
278. Ogasawara M., Sasa H., Kajiura S., Aoki K., Yagami Y. Successful management of congenital protein C deficiency with recurrent pregnancy loss. Int J Gynaecol Obstet. 50(2):1995;185-187.
279. Richards E. M., Makris M., Preston F. E. The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss. Br J Haematol. 98(3):1997;660-661.
280. Harker L. A., Hanson S. R., Kelly A. B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost. 78:1997;736.
281. Eigler A., Sinha B., Hartmann G., Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today. 18(10):1997;487-492.